Neil T Mason1, Gillian C Bell2, Rod E Quilitz3, John N Greene3, Howard L McLeod2. 1. H. Lee Moffitt Cancer Center, 12902 Magnolia Dr., MRC-CANCONT, Tampa, FL 33612, USA neil.mason@moffitt.org. 2. H. Lee Moffitt Cancer Center, 12902 Magnolia Dr., MRC-CANCONT, Tampa, FL 33612, USA. 3. H. Lee Moffitt Cancer Center, 12902 Magnolia Dr., FOB-3 BMT PROG, Tampa, FL 33612, USA.
Abstract
OBJECTIVES: The objective of this study was to determine the economic impact of proactive, CYP2C19 genotype-guided voriconazole prophylaxis in AML. METHODS: An Excel-based model was created to project the cost of treating a simulated cohort of severely neutropenic AML patients undergoing antifungal prophylaxis. The model compares (i) standard prophylactic dosing with voriconazole and (ii) CYP2C19 genotyping of all AML patients to guide voriconazole dosing and prescribing. RESULTS: Based on the model, genotype-guided dosing of voriconazole conservatively spares 2.3 patients per year from invasive fungal infections. Implementing proactive genotyping of all AML patients in a simulated 100 patient cohort is expected to save a total of $41467 or $415 per patient. CONCLUSIONS: The model, based on the robust literature of clinical and economic data, predicts that proactive genotype-guided voriconazole prophylaxis is likely to yield modest cost savings while improving patient outcomes. The primary driver of savings is the avoidance of expensive antifungal treatment and extended hospital stays, costing $30 952 per patient, in patients succumbing to fungal infection.
OBJECTIVES: The objective of this study was to determine the economic impact of proactive, CYP2C19 genotype-guided voriconazole prophylaxis in AML. METHODS: An Excel-based model was created to project the cost of treating a simulated cohort of severely neutropenic AMLpatients undergoing antifungal prophylaxis. The model compares (i) standard prophylactic dosing with voriconazole and (ii) CYP2C19 genotyping of all AMLpatients to guide voriconazole dosing and prescribing. RESULTS: Based on the model, genotype-guided dosing of voriconazole conservatively spares 2.3 patients per year from invasive fungal infections. Implementing proactive genotyping of all AMLpatients in a simulated 100 patient cohort is expected to save a total of $41467 or $415 per patient. CONCLUSIONS: The model, based on the robust literature of clinical and economic data, predicts that proactive genotype-guided voriconazole prophylaxis is likely to yield modest cost savings while improving patient outcomes. The primary driver of savings is the avoidance of expensive antifungal treatment and extended hospital stays, costing $30 952 per patient, in patients succumbing to fungal infection.
Authors: C T Rieger; O A Cornely; T Hoppe-Tichy; M Kiehl; H Knoth; M Thalheimer; U Schuler; A J Ullmann; B Ehlken; H Ostermann Journal: Mycoses Date: 2012-04-03 Impact factor: 4.377
Authors: Daoud Al-Badriyeh; Monica Slavin; Danny Liew; Karin Thursky; Maria Downey; Andrew Grigg; Ashish Bajel; Kay Stewart; David C M Kong Journal: J Antimicrob Chemother Date: 2010-03-17 Impact factor: 5.790
Authors: Arwa Hassan; Jürgen Burhenne; Klaus-Dieter Riedel; Johanna Weiss; Gerd Mikus; Walter E Haefeli; David Czock Journal: Ther Drug Monit Date: 2011-02 Impact factor: 3.681
Authors: Siow-Chin Heng; Monica A Slavin; Daoud Al-Badriyeh; Sue Kirsa; John F Seymour; Andrew Grigg; Karin Thursky; Ashish Bajel; Roger L Nation; David C M Kong Journal: J Antimicrob Chemother Date: 2013-03-13 Impact factor: 5.790
Authors: Joseph Menzin; Juliana L Meyers; Mark Friedman; John R Perfect; Amelia A Langston; Robert P Danna; George Papadopoulos Journal: Am J Health Syst Pharm Date: 2009-10-01 Impact factor: 2.637
Authors: J Kevin Hicks; Rod E Quilitz; Rami S Komrokji; Timothy E Kubal; Jeffrey E Lancet; Yanina Pasikhova; Dahui Qin; Wonhee So; Gisela Caceres; Kerry Kelly; Yasmina S Salchert; Kevin Shahbazian; Farnoosh Abbas-Aghababazadeh; Brooke L Fridley; Ana P Velez; Howard L McLeod; John N Greene Journal: Clin Pharmacol Ther Date: 2019-11-01 Impact factor: 6.875